midazolam and fluconazole

midazolam has been researched along with fluconazole in 27 studies

Research

Studies (27)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (18.52)	18.2507
2000's	10 (37.04)	29.6817
2010's	11 (40.74)	24.3611
2020's	1 (3.70)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Ahman, M; Holmén, AG; Wan, H	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J	1
Han, G; Ji, C; Jiang, Y; Li, Z; Liu, N; Sheng, C; Tu, J; Wang, Y	1
Idänpään-Heikkilä, JJ; Mattila, MJ; Törnwall, M; Vainio, P; Vanakoski, J	1
Ahonen, J; Neuvonen, PJ; Olkkola, KT	2
Gibbs, MA; Kunze, KL; Shen, DD; Thummel, KE	1
Ahonen, J; Neuvonen, PJ; Olkkola, KT; Takala, A	1
Hoffer, C; Kharasch, ED; Sheffels, P; Walker, A	1
Brown, HS; Chadwick, A; Houston, JB	1
Blough, DK; Dees, EC; Givens, RC; Hawke, RL; Isoherranen, N; Iwanaga, K; Lamba, JK; Ludington, SR; Paine, MF; Pusek, SN; Schuetz, EG; Thummel, KE; Watkins, PB	1
Boulenc, X; Hachad, H; Levy, RH; Ragueneau-Majlessi, I; Rauch, C	1
Atkins, WM; Isoherranen, N; Paine, MF; Thummel, KE; Yang, J	1
Obach, RS	1
Namiki, N; Tanaka, S; Uchida, S	1
Berke, K; Joo, H; KuKanich, B; Orchard, R; Rankin, D	1
Blank, A; Burhenne, J; Elbe, A; Foerster, KI; Haefeli, WE; Mikus, G; Rose, P	1

Reviews

1 review(s) available for midazolam and fluconazole

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

5 trial(s) available for midazolam and fluconazole

Article	Year
150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects. International journal of clinical pharmacology and therapeutics, 1995, Volume: 33, Issue:9 Topics: Adult; Antifungal Agents; Double-Blind Method; Drug Interactions; Female; Flicker Fusion; Fluconazole; Humans; Hypnotics and Sedatives; Male; Memory; Midazolam; Psychomotor Performance	1995
The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesthesia and analgesia, 1996, Volume: 82, Issue:3 Topics: Administration, Oral; Adult; Antifungal Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Fluconazole; Humans; Hypnotics and Sedatives; Injections, Intravenous; Itraconazole; Male; Metabolic Clearance Rate; Midazolam; Placebos; Psychomotor Performance	1996
Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. European journal of clinical pharmacology, 1997, Volume: 51, Issue:5 Topics: Administration, Oral; Adult; Analysis of Variance; Anti-Anxiety Agents; Antifungal Agents; Cross-Over Studies; Double-Blind Method; Drug Administration Routes; Drug Interactions; Female; Fluconazole; Humans; Injections, Intravenous; Male; Midazolam	1997
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. Journal of clinical pharmacology, 2005, Volume: 45, Issue:10 Topics: Administration, Oral; Adult; Alfentanil; Analgesics, Opioid; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Fluconazole; Humans; Injections, Intravenous; Liver; Male; Midazolam; Miosis; Sensitivity and Specificity; Time Factors	2005
Clinical and pharmacokinetic interactions between oral fluconazole and intravenous ketamine and midazolam in dogs. Veterinary anaesthesia and analgesia, 2019, Volume: 46, Issue:6 Topics: Administration, Intravenous; Administration, Oral; Animals; Area Under Curve; Dogs; Drug Interactions; Female; Fluconazole; Half-Life; Ketamine; Male; Midazolam	2019

Other Studies

21 other study(ies) available for midazolam and fluconazole

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5 Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution	2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6 Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity. Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1 Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water	2018
Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis. Journal of medicinal chemistry, 2019, 03-14, Volume: 62, Issue:5 Topics: Animals; Antifungal Agents; Blood-Brain Barrier; Brain; Carbolines; Colony Count, Microbial; Cryptococcus neoformans; DNA Breaks, Double-Stranded; Drug Discovery; Humans; Meningitis, Cryptococcal; Mice; Microbial Sensitivity Tests; Structure-Activity Relationship	2019
Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug metabolism and disposition: the biological fate of chemicals, 1999, Volume: 27, Issue:2 Topics: Algorithms; Antifungal Agents; Blotting, Western; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Drug Interactions; Enzyme Inhibitors; Fluconazole; Humans; In Vitro Techniques; Intestine, Small; Ketoconazole; Kinetics; Microsomes; Microsomes, Liver; Midazolam; Mixed Function Oxygenases	1999
Interaction between fluconazole and midazolam in intensive care patients. Acta anaesthesiologica Scandinavica, 1999, Volume: 43, Issue:5 Topics: Adult; Analysis of Variance; Antifungal Agents; Critical Care; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fluconazole; Follow-Up Studies; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Positive-Pressure Respiration; Renal Insufficiency	1999
Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:11 Topics: Animals; Catalysis; Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Inhibitors; Fluconazole; Fluoxetine; Fluvoxamine; Hepatocytes; Ketoconazole; Kinetics; Male; Miconazole; Microsomes, Liver; Midazolam; Phenytoin; Quinine; Rats; Rats, Sprague-Dawley; Tolbutamide	2007
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:1 Topics: Adolescent; Adult; Animals; Baculoviridae; Blotting, Western; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; Female; Fluconazole; Genetic Vectors; Genotype; Humans; In Vitro Techniques; Insecta; Male; Microsomes, Liver; Midazolam; Middle Aged; Substrate Specificity; Transfection	2008
Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Current drug metabolism, 2007, Volume: 8, Issue:8 Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Interactions; Enzyme Inhibitors; Erythromycin; Fluconazole; Ketoconazole; Midazolam; Substrate Specificity; Verapamil	2007
Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:3 Topics: Allosteric Regulation; Area Under Curve; Biomarkers; Cytochrome P-450 CYP3A; Drug Interactions; Fluconazole; Humans; Midazolam	2012
Heterotropic effects on drug-metabolizing enzyme activities: in vitro curiosity emerges as a clinically meaningful phenomenon (perhaps?). Clinical pharmacology and therapeutics, 2012, Volume: 91, Issue:3 Topics: Cytochrome P-450 CYP3A; Fluconazole; Humans; Midazolam	2012
Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats. Biopharmaceutics & drug disposition, 2014, Volume: 35, Issue:4 Topics: Animals; Caffeine; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dextromethorphan; Drug Interactions; Fluconazole; Fluvoxamine; Ketoconazole; Losartan; Male; Midazolam; Omeprazole; Rats, Sprague-Dawley	2014
Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. European journal of clinical pharmacology, 2022, Volume: 78, Issue:6 Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Fluconazole; Humans; Midazolam; Omeprazole; Rifampin; Sodium Bicarbonate; Yohimbine	2022